Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Renovorx Inc (NQ: RNXT )

1.290 +0.080 (+6.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Renovorx Inc

< Previous 1 2 3 4 5 6 7 Next >
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
From RenovoRx, Inc.
Via Business Wire
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the LD Micro Invitational XIII Conference
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
From RenovoRx, Inc.
Via Business Wire
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
From RenovoRx, Inc.
Via Business Wire
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From RenovoRx, Inc.
Via Business Wire
US Stocks Open Higher; Dow Jumps 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Thursday. Following the market opening Thursday, the Dow traded up 0.48% to 32,874.88 while the NASDAQ rose 0.68%... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
RenovoRx’s Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
RenovoRx's Targeted Prostate Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care
Via Benzinga
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fueled Breakout ($RNXT)
Via AB Newswire
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Shares Surge 117% YTD As Multiple Catalysts Come Into Focus ($RNXT)
Via AB Newswire
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Shares Rally As RenovoTAMP Cancer Treatment Platform Continues To Attract Sector Attention ($RNXT)
Via AB Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
RenovoRX's Latest Innovative Technology Creates New Hope for Chemotherapy Patients
RenovoRx takes existing chemotherapies and makes them more effective and less invasive at the same time, by being able to concentrate most of the chemotherapy agent on the tumor itself. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.